Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
Following the discussions at Investigator Meetings during November 2020 - February 2021, in which doctors and representatives of the clinics included in the company's clinical study participated, a status update follows in light of the current pandemic. Participating hospitals are University College London Hospital, Princess Margaret Cancer Centre in Toronto, University of Pennsylvania Hospital in Philadelphia and Memorial Sloan Kettering Cancer Center in New York.In the first part of the clinical studies, SpectraCure has achieved its goal of optimizing the drug dose and compiling the